Safety information
Namenda (memantine HCl) is contraindicated in patients with known hypersensitivity to memantine HCl or to any excipients used in the formulation. The most common adverse events reported with Namenda vs. placebo (≥5% and higher than placebo) were dizziness, confusion, headache, and constipation. In patients with severe renal impairment, the dosage should be reduced.
Namenda is indicated for the treatment of moderate to severe Alzheimer's disease.
Full Prescribing Information | Global Reference List
© 2007 Forest Pharmaceuticals, Inc
WebMD does not endorse any specific product, service, or treatment.
Namenda Works Differently to Treat Alzheimer's Disease
Namenda is safe and effective
Starting Namenda is easy
When to ask about Namenda therapy
Listen in to the Experts
Agitation. Wandering. Aggression. How does a caregiver cope withthese challenging behaviors over a period of several years? Dr. George Grossberg provides insight on what to expect as the disease progresses, as well as tips for handling caregiver frustration.
Series moderated by: Warachal E. Faison, MD, Assistant Director of the Institute of Research Minority Training on Mental Health and Aging (IRMMA) and Clinical Director of the Alzheimer's Research and Clinical Programs at the Medical University of South Carolina.


